Base to Base Biotech Podcast: Natural Killer Cell Therapy
In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents.
In a this episode of the ๐๐ฎ๐๐ฒ ๐๐ผ ๐๐ฎ๐๐ฒ ๐๐ถ๐ผ๐๐ฒ๐ฐ๐ต ๐ฃ๐ผ๐ฑ๐ฐ๐ฎ๐๐, Lisa Guerrettaz, Executive Director, Pharmacology and Translational Science at Artiva Biotherapeutics, discusses how the limitations of currently approved treatments are driving the development of new and potentially more durable therapeutic approaches for autoimmune diseases.
The conversation examines lessons from prior approaches in autoimmune disease, the limitations of current treatment sequencing, and how these insights are informing the clinical development of AlloNKยฎ in rheumatoid arthritis.
The conversation explores:
- Why existing therapies often fail to deliver sustained disease control in rheumatoid arthritis
- What deep B-cell depletion means biologically, and how insights from CAR-T in autoimmune disease have shaped current thinking around immune reset
- How AlloNK is being developed to align depth of immune effect with real-world treatment considerations